Pharmacokinetic aspects of a new dry cow therapy

Cattle Practice

Volumn 13, Issue 3, 2005, Pages 227-230

  Ehinger, A M ^a   Allan, M J ^a   Hartmann, M ^a   Zschiesche, E ^a   Thomas, E ^a  

^a Intervet Innovation GmbH   (Germany)

Author keywords

Antibiotics; Dry cow; Intramammary; Mastitis; Particle size; Pharmacokinetics; Tissue distribution

Indexed keywords

BACTERIA (MICROORGANISMS); POSIBACTERIA;

EID: 28044468638     PISSN: 09691251     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Ehinger A.M., Kietzmann M. (2000a) Tissue distribution of benzylpenicillin after intramammary administration in the isolated perfused bovine udder. Journal of Veterinary Pharmacology and Therapeutics 23: 303-310.
2. Ehinger A.M., Kietzmann M. (2000b) Tissue distribution of oxacillin and ampicillin in the isolated perfused bovine udder. Journal of Veterinary Medicine A 47: 157-168.
3. Ehinger A.M., Ehinger B., Kietzmann M. (2001) Pharmazeutische und pharmakologische Anmerkungen zum Einsatz von Trockenstellern bei Milchkühen. Tierärztliche Praxis G 29: 114-121.
4. Ehinger A.M., Allan M.J., Hartmann M., Zschiesche E., Thomas E. (2004) Depletion of residues in edible tissues and milk following treatment with a new cefquinome dry cow formulation. Le Médecin Vétérinaire du Québec 34: 460.
5. Ehinger A.M., Schmidt H., Kietzmann M. (2005) Tissue distribution of cefquinome after intramammary and "systemic" administration in the isolated perfused bovine udder. The (British) Veterinary Journal, in press.
6. Ganière J-P., Mangion C., Péridy M. (2004) Détermination des concentrations minimales inhibitrices et bactéricides de la cefquinome, la marbofloxacine, la tylosine et la spiramycine en solution dans du lait vis-à-vis de bactéries isolées de mammites bovines. Revue de Médecine Vétérinaire. 155, 8-9: 411-416.
7. Green M., Huxley J., Bradley A. (2002) A rational approach to dry cow therapy - 1. Udder health priorities during the dry period. In practice 24: 582-587.
8. Guérin-Faublée V., Carret G., Houffschmitt P. (2003) In vitro activity of 10 antimicrobial agents against bacteria isolated from cows with clinical mastitis. The Veterinary Record 152: 466-471.
9. Sader H.S., Jones R.N. (1993) The fourth-generation cephalosporins: antimicrobial activity and spectrum definitions using cefpirome as an example. The Antimicrobial Newsletter 9: 9-16.
10. Schmid P., Thomas V. (2002) Cefquinome - eight years antimicrobial susceptibility surveillance in cattle. XXII World Buiatrics Congress, p. 147, 456-764.
11. Shpigel N.Y., Schmid P. (1997) Ein Beitrag zur Behandlung der akuten Mastitis des Rindes mit Cefquinom. Tierärztliche Praxis 25: 200-206.
12. Shpigel N.Y., Levin D., Winkler M., Saran A., Ziv G., Böttner A. (1997). Efficacy of cefquinome for treatment of cows with mastitis experimentally induced using Escherichia coli. Journal of Dairy Science 80: 318-323.
13. Soback S., Saran A. (2005) New antimicrobial agents in mastitis therapy. In: Hogeveen H. (ed.): Mastitis in dairy production - current knowledge and future solutions. Wageningen Academic Publishers, p. 53-57.
14. Sol J., Sampimon O., Barkema H., Kock P., Mevius D. (2005) Sensitivity patterns of streptococci, E. coli and coliforms isolated from bovine mastitis in The Netherlands. In: Hogeveen H. (ed.): Mastitis in dairy production - current knowledge and future solutions. Wageningen Academic Publishers, p. 825.
15. Thomas E., Heuwieser W., Ehinger A.M., Allan M.J., Hartmann M., Schmid P. (2003) Pharmacokinetics of cefquinome in the bovine dry udder secretions used as the basis for a dose-titration of a new intramammary cefquinome formulation. Journal of Veterinary Pharmacology and Therapeutics 26 (Suppl. 1): 117.
16. Thomas E., Zschiesche E., Knoppe T. (2004) Efficacy of a new cefquinome dry cow formulation in a controlled and partially blinded field study. Le Médecin Vétérinaire du Québec 34: 496.